FIELD: medicine.
SUBSTANCE: invention relates to a method for the treatment of a condition that is mediated by cystic fibrosis transmembrane conductivity regulator (hereinafter – CFTR) in a patient, including injection to a patient of a Compound (I) represented by the following structural formula:
, or its pharmaceutically acceptable salt in the amount from 150 mg to 200 mg once a day, as well as to a pharmaceutical composition intended for the treatment of a condition mediated by CFTR in a patient, including a pharmaceutically acceptable carrier or diluent and from 150 mg to 200 mg of a compound represented by the following structural formula:
, or its pharmaceutically acceptable salt.
EFFECT: obtaining compounds for the treatment of a condition mediated by CFTR.
15 cl, 4 tbl, 7 ex, 12 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| FORMULATIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL)CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZONIC ACID | 2013 |
|
RU2644723C2 |
| NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, THEIR DERIVATIVES AND THEIR PRODUCTION METHODS | 2015 |
|
RU2771275C2 |
| OLIGONUCLEOTIDES FOR MAKING CHANGE IN SEQUENCE OF TARGET RNA MOLECULE PRESENT IN LIVING CELL | 2013 |
|
RU2663110C2 |
| STABLE COMPOSITIONS OF ASCORBIC ACID AND METHODS OF THEIR USE | 2018 |
|
RU2799046C2 |
| NEW TREATMENT | 2015 |
|
RU2688191C2 |
| SILICON-CONTAINING IVACAFTOR ANALOGUES | 2017 |
|
RU2796112C2 |
| ORGANIC COMPOUNDS | 2015 |
|
RU2785871C2 |
| ORGANIC COMPOUNDS | 2017 |
|
RU2733975C2 |
| NEW COMPOSITIONS AND METHODS | 2018 |
|
RU2767410C2 |
| ORGANIC COMPOUNDS | 2015 |
|
RU2728787C2 |
